Quick Search 
Drugs of the Future
Register or sign in

  
 
  
Drugs Fut 2021, 46(7): 515
ISSN 0377-8282
Copyright 2021 Clarivate
CCC: 0377-8282
DOI: 10.1358/dof.2021.46.7.3304876
 
 
Somatrogon. Long-acting human growth hormone, Treatment of human growth hormone deficiency
Ribeiro, D.
 
 
Growth hormone deficiency (GHD) is caused by inadequate secretion of growth hormone (GH). Children with GHD often present with growth failure and severe short stature, while adult-onset GHD is characterized by unfavorable changes in cardiovascular function, central obesity and osteoporosis. Despite the efficacy of recombinant human growth hormone (rhGH) therapy, the need for daily injections often leads to poor treatment adherence. Somatrogon (MOD-4023) is a long-acting rhGH developed to provide a once-weekly alternative to the current daily rhGH treatment scheme. In a phase II clinical trial in GHD children, somatrogon had a markedly longer half-life relative to rhGH, compatible with weekly treatment regimens. The results of the pivotal phase III study showed that once-weekly somatrogon was noninferior to daily hGH, and the open-label study extension is currently ongoing.


Full Text: PDF 
 
  



© Clarivate. All rights reserved.
Copyright NoticeTerms of UsePrivacy StatementCookie PolicyManage cookie preferences